Last checked at 21 Jul 2009 12:29
Stock Exchange announcement
FOR release: Tuesday 21 July 2009
CELSIS INTERNATIONAL PLC
("Celsis", "the Company" or "the Group")
Results of AGM
21 July 2009: At the Annual General Meeting of Celsis, held today, all resolutions were duly passed.
| Enquiries: |
|
|
|
|
| Celsis International plc | Tel: +44 (0) 1223 598 428 |
| Jay LeCoque, Chief Executive Officer |
|
| Robyn LaLonde, Executive Assistant to CEO |
|
|
|
|
| Financial Dynamics | Tel: +44 (0) 20 7831 3113 |
| Jonathan Birt Susan Quigley |
|
|
Celsis International plc |
|
Notes to editors
Celsis International plc
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis business has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange's Main Market (CEL.L).
Celsis Rapid Detection utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market.
Celsis Analytical Services provides cost effective outsourced analytical laboratory services to the pharmaceutical and consumer products industries. Its comprehensive service offerings include a full spectrum of laboratory services used in the ongoing manufacture of our customers' products ranging from analytical chemistry and biological sciences to stability storage and testing.
Celsis In Vitro Technologies (IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical industry. IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or research on those compounds that will not be properly metabolised by the human liver.
Further information can be found on its website at www.celsis.com.